- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
National Diagnostics to merge with AES
Brandon, FL-based imaging services chain National Diagnostics has signed a definitive agreement to merge with integrated delivery system firm American Enterprise Solutions of Tampa, FL. Under the terms of the agreement, NDI shareholders will maintain a
Brandon, FL-based imaging services chain National Diagnostics has signed a definitive agreement to merge with integrated delivery system firm American Enterprise Solutions of Tampa, FL. Under the terms of the agreement, NDI shareholders will maintain a 12.3% interest in the new company, with AES shareholders holding an 87.7% interest. The combined company will have projected 1998 pre-tax profits of $4.5 million on revenues of roughly $46 million, according to the firms.
NDI agreed to the merger after suffering financial difficulties related to the company's rapid expansion. NDI had fallen behind on payments to vendors and lessors, and the firm's stock was delisted from the NASDAQ exchange in August 1997. AES was founded in September 1997 with the goal of acquiring companies to create community healthcare delivery systems.
In other NDI news, Jugal Taneja has resigned his post as chairman and CEO. COO Curtis Alliston has assumed the role of acting CEO.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
